Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 58, Issue 2, 1999, Pages 79-84

  Haagsma, Cees J ^a   Blom, Henk J ^b   Van Riel, Piet L C M ^b   Van't Hof, Martin A ^b   Giesendorf, Belinda A J ^b   Van Oppenraaij Emmerzaal, Dinny ^b   Van De Putte, Levinus B A ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTICLE; DRUG EFFICACY; DRUG MIXTURE; DRUG SCREENING; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0033007397     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.2.79     Document Type: Article

References (28)

1. 1 Felson DT, Andersen JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthitis. A metanalysis of published trials. Arthritis Rheum 1992;35:1117-25.
2. 2 Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs 1994;47:25-50.
3. 3 Selhub J, Dhar J, Rosenberg IH. Inhibition of folate enzymes by sulfasalazine. J Clin Invest 1978;61:221-4.
4. 4 Bird HA. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid-Which is the active moiety in rheumatoid arthritis? Br J Rheumatol 1995;34 (suppl 2):16-19.
5. 5 Franklin JL, Rosenberg IH. Impaired folic acid absorption in inflammatory bowel disease: effects of salicyazosulfapyridine (azulfidine). Gastroenterology 1973;64:517-25.
6. 6 Grindulis KA, McConkey B. Does sulfasalazine cause folate deficiency in rheumatoid arthritis? Scand J Rheumatol 1985;14:265-70.
7. 7 Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 1988;31:906-8.
8. 8 Joyce DA, Will RK, Huffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in p atients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991;50:913-14.
9. 9 Morgan SL, Babbott JE, Vaugh WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double blind, placebo-controlled trial. Ann Intern Med 1994;121:833-41.
10. 10 Hanrahan PS, Russell AS. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol 1988;15:1078-80.
11. 11 Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1990;17:1158-61.
12. 12 Weinblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 1993;20:950-2.
13. 13 Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 1993;35:795-803.
14. 14 Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
15. 15 Nesher G, Moore TL. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl-donors and spermidine. Arthritis Rheum 1990;33:954-9.
16. 16 Haagsma CJ, van Riel PLCM, van de Putte LBA. Combination of methotrexate and sulphasalazine versus methotrexate alone. A randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol 1994;33:1049-55.
17. 17 Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. Pharmacol Ther 1989;46:510-20.
18. 18 Van der Put NMJ, Eskes TKAB, Blom HJ. Is the common 677C-T mutation in the methylenetetrahydrofolate reductase a risk factor for neural tube defects? A mega-analysis. Q J Med 1997;90:111-15.
19. 19 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995;10:111-13.
20. 20 Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346: 1070-1.
21. 21 Van der Heijde DMFM, van't Hoff MA, van Riel PLCM, Theunisse LAM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
22. 22 Te Poele-Pothoff MTWB, van den Berg M, Franken DG, Boers GHJ, Jakobs C, de Kroon IFI, et al. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995;32:218-20.
23. 23 Mooij PNM, Thomas CMG, Doesburg WH, Eskes TKAB. Multivitamin supplementation in oral contraceptive users. Contraception 1991;44:277-88.
24. 24 Haagsma CJ, van Riel PLCM, de Jong AJL, van de Putte LBA. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double blind, 52 week clinical trial. Br J Rheumatol 1997;36:1082-8.
25. 25 Morgan SL, Baggott JE, Refsum H, Ueland PE. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clin Pharmacacol 1991;50: 547-56.
26. 26 Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents defecient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998;25: 441-6.
27. 27 Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Poyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 1985;76:907-12.
28. 28 Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.